NKGen Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKGN research report →
Price Chart
About the company
NKGen Biotech, Inc. , a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors.
- CEO
- Paul Y. Song
- IPO
- 2021
- Employees
- 26
- HQ
- Santa Ana, CA, US
Get TickerSpark's AI analysis on NKGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.45M
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 150.91%
- ROIC
- -112358.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-26,966,000
- Net Income
- $-44,286,000+46.6%
- EPS
- $-1.54+71.4%
- OCF Growth
- +4.9%
- FCF Growth
- +5.1%
- 52W High
- $0.77
- 52W Low
- $0.00
- 50D MA
- $0.05
- 200D MA
- $0.13
- Beta
- 0.72
- RSI (14)
- 51
- Avg Volume
- 8.66K
No earnings-call transcripts are available for NKGN yet.
- Free Float
- 8.5%
- Shares Outstanding
- 130.60M
- Float Shares
- 11.15M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Meteora Capital, LLC | 2.76M | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 25 | CFIC-2015 NV Family Investments, LLC | buy | 39,339,103 |
| May 27, 25 | CFIC-2015 NV Family Investments, LLC | buy | 19,669,552 |
| May 5, 25 | Song Paul Y. | buy | 41,699,449 |
| May 5, 25 | Song Paul Y. | buy | 20,849,725 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | other | 63,634 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | sell | 757,942 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | sell | 93,334 |
| Dec 2, 24 | Graf Acquisition Partners IV LLC | sell | 713,357 |
| Dec 16, 24 | Graf Acquisition Partners IV LLC | sell | 1,212,707 |
| Dec 2, 24 | Graf Acquisition Partners IV LLC | other | 97,232 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NKGN coverage
Recent articles, reports, and earnings notes.
No research on NKGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NKGN report →NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
globenewswire.com · Sep 15
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
globenewswire.com · Sep 10
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions
globenewswire.com · Jul 2
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
globenewswire.com · Jul 2
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
globenewswire.com · May 19
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
globenewswire.com · Apr 9
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
globenewswire.com · Mar 23
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
globenewswire.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.